Chimeric Therapeutics Ltd (CHM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Chimeric Therapeutics Ltd (CHM) has a cash flow conversion efficiency ratio of 1.268x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-3.84 Million ≈ $-2.72 Million USD) by net assets (AU$-3.03 Million ≈ $-2.14 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Chimeric Therapeutics Ltd to measure how much of total assets are equity-financed.
Chimeric Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Chimeric Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Chimeric Therapeutics Ltd to evaluate the quality of earnings relative to operating cash generation.
Chimeric Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Chimeric Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Oakridge International Ltd
AU:OAK
|
-0.447x |
|
Cho Thavee Public Company Limited
BK:CHO
|
-0.006x |
|
Reneuco Berhad
KLSE:7130
|
0.013x |
|
Macfarlane Group PLC
LSE:MACF
|
0.103x |
|
CardioComm Solutions Inc.
V:EKG
|
0.215x |
|
Erech Finance Cahalacha Ltd
TA:EFNC
|
-0.213x |
|
Reliance Global Group, Inc.
NASDAQ:EZRA
|
-0.077x |
|
Ausmon Resources Ltd
AU:AOA
|
-0.232x |
Annual Cash Flow Conversion Efficiency for Chimeric Therapeutics Ltd (2020–2025)
The table below shows the annual cash flow conversion efficiency of Chimeric Therapeutics Ltd from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see CHM company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$1.97 Million ≈ $1.40 Million |
AU$-7.28 Million ≈ $-5.15 Million |
-3.685x | -20.75% |
| 2024-06-30 | AU$2.47 Million ≈ $1.75 Million |
AU$-7.54 Million ≈ $-5.33 Million |
-3.052x | -5.87% |
| 2023-06-30 | AU$5.66 Million ≈ $4.01 Million |
AU$-16.32 Million ≈ $-11.54 Million |
-2.882x | -463.33% |
| 2022-06-30 | AU$25.71 Million ≈ $18.19 Million |
AU$-13.15 Million ≈ $-9.31 Million |
-0.512x | -45.42% |
| 2021-06-30 | AU$25.13 Million ≈ $17.78 Million |
AU$-8.84 Million ≈ $-6.26 Million |
-0.352x | -166.12% |
| 2020-06-30 | AU$-63.91K ≈ $-45.22K |
AU$-34.01K ≈ $-24.06K |
0.532x | -- |
About Chimeric Therapeutics Ltd
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurre… Read more